title: Where now for insulin glargine--a time for pragmatic medicine?
authors.affiliation: Sheffield Hallam University, Sheffield, UK. george.thomson66@ntlworld.com
authors.forename: G A
authors.initials: GA
authors.lastname: Thomson
authors.forename: R
authors.initials: R
authors.lastname: Craig
mesh_terms: D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects*; D007328:Insulin / Q000009:adverse effects / Q000031:analogs & derivatives*; D000069036:Insulin Glargine; D049528:Insulin, Long-Acting; D009369:Neoplasms / Q000139:chemically induced*; D012307:Risk Factors
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin; D049528:Insulin, Long-Acting; D000069036:Insulin Glargine